Beyond CGRP: The calcitonin peptide family as targets for migraine and pain.

Tayla A Rees, Erica R Hendrikse, Debbie L Hay, Christopher S Walker

British journal of pharmacology 2022 Feb

filter terms:

The CGRP system has emerged as a key pharmacological target for the treatment of migraine. However, some individuals who suffer from migraine have low or no response to anti-CGRP or other treatments, suggesting the need for additional clinical targets. CGRP belongs to the calcitonin family of peptides, which includes calcitonin, amylin, adrenomedullin and adrenomedullin 2. These peptides display a range of pro-nociceptive and anti-nociceptive actions, in primary headache conditions such as migraine. Calcitonin family peptides also show expression at sites relevant to migraine and pain. This suggests that calcitonin family peptides and their receptors, beyond CGRP, may be therapeutically useful in the treatment of migraine and other pain disorders. This review considers the localisation of the calcitonin family in peripheral pain pathways and discusses how they may contribute to migraine and pain. LINKED ARTICLES: This article is part of a themed issue on Advances in Migraine and Headache Therapy (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.3/issuetoc. © 2021 The British Pharmacological Society.

Citation

Tayla A Rees, Erica R Hendrikse, Debbie L Hay, Christopher S Walker. Beyond CGRP: The calcitonin peptide family as targets for migraine and pain. British journal of pharmacology. 2022 Feb;179(3):381-399